Article Text

Download PDFPDF
P154 Safety of tiotropium in pre-school children with symptomatic persistent asthma
  1. H Bisgaard1,
  2. M Vandewalker2,
  3. L Graham3,
  4. P Moroni-Zentgraf4,
  5. M Engel4,
  6. G El Azzi4,
  7. SD Vulcu5,
  8. H Finnigan6,
  9. EJLE Vrijlandt7
  1. 1University of Copenhagen, Department of Clinical Medicine, Gentofte Hospital, Copenhagen, Denmark
  2. 2Clinical Research of the Ozarks, Inc., Columbia, MO, USA
  3. 3Children’s Healthcare of Atlanta, Atlanta, GA, USA
  4. 4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim am Rhein, Germany
  5. 5Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riss, Germany
  6. 6Clinical Development and Medical Affairs/TA Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, UK
  7. 7Department of Paediatric Pulmonology and Paediatric Allergy, Beatrix Children’s Hospital, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands


Introduction and objectives Asthma is the most common chronic disease of childhood (GINA 2015). For pre-school children whose asthma symptoms are not well controlled on inhaled corticosteroids, limited options are available for further treatment. Here, we evaluated the safety of once-daily (QD) tiotropium Respimat® (tioR) in patients aged 1–5 years with symptomatic persistent asthma.

Methods A Phase II/III, randomised, double-blind, placebo-controlled, parallel-group trial (NCT01634113) of tioR 5 μg, tioR 2.5 μg or placebo Respimat® (pboR), administered QD in the afternoon for 12 weeks, each as add-on to usual maintenance therapy. Safety data, including post hoc analysis of a composite exacerbation end point derived from adverse events (AEs), are reported.

Results No AEs leading to treatment discontinuation or death were reported. The proportion of patients with any AEs was higher with pboR (73.5%) than with tioR 5 μg (58.1%) and 2.5 μg (55.6%). Two patients each in the tioR 5 μg (6.5%) and pboR (5.9%) groups were reported with drug-related AEs. Three patients, all in the pboR group, were reported with serious AEs. Asthma exacerbation/worsening was reported by fewer patients in the tioR 5 μg and tioR 2.5 μg groups compared with the pboR group (Table).

Conclusion Once-daily tiotropium Respimat® add-on to maintenance therapy is well tolerated and may reduce exacerbations in pre-school children with symptomatic persistent asthma.

Abstract P154 Table 1

Composite asthma endpoint: Asthma exacerbation (broad) with pneumonia plus asthma worsening

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.